EN IT

updated 12.12.2017

Hepa-IC Literature

88. Cavalletto L, Aliberti C, Romano A, Biasiolo A, Pontisso P, Angeli P, Chemello L. Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer. EASL International Liver Congress (ILC). Amsterdam, Holland. 2017.
87. Cavalletto L, Aliberti C, Zanus G, Cillo U, Pontisso P, Meascoli C, Angeli P, Chemello L. Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: a real-life cohort study. EASL HCC Summit. Geneva, Switzerland. 2017.
86. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Ferrer MT, Liu C, Pontisso P, Romero-Gómez M. Utility of SCCA-IgM levels in the prediction of hepatocellular carcinoma in cirrhotic patients. EASL HCC Summit. Geneva, Switzerland. 2017.
85. Gringeri E, Di Giunta M, Biasiolo A, D'Amico FE, Fasolo E, Pontisso P, Cillo U. Serum and bile squamous cell carcinoma antigen 1 (SCCA1) detection: a new diagnostic approach in patients with perihilar cholangiocarcinoma (pCCA). The Liver Meeting-American Association for the Study of Liver Diseases (AASLD). Washington DC, USA. 2017. doi: 10.1002/hep.29501
84. Guarino M, Di Costanzo GG, Gallotta A, Tortora R, Paneghetti L, Auriemma F, Tuccillo C, Fassina G, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. 77(6):448-453. 2017. doi: 10.1080/00365513.2017.1336569
83. Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen serum determination as a biomarker of Barrett esophagus and esophageal cancer: a phase III study. J. Clin. Gastroenterol.. E-pub ahead of print. 2017. doi: 10.1097/MCG.0000000000000790
82. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. In HCV infected patients with cirrhosis Squamous Cell Carcinoma Antigen (SCCA)-IgM levels may contribute to identify the individual risk of HCC development after antiviral therapy. Dig Liver Dis. 49S:e48. 2017. doi: 10.1016/j.dld.2017.01.099
81. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. In hepatitis C infected patients with cirrhosis squamous cell carcinoma antigen (SCCA)-IgM levels may contribute to identify the individual risk of hepatocellular carcinoma development after antiviral therapy. EASL International Liver Congress (ILC). Amsterdam, Holland. 2017.
80. Ricco G, Cavallone D, Pontisso P, Fassina G, Gallotta A, Colombatto P, Oliveri F, Romagnoli V, Coco B, Salvati A, Bonino F, Brunetto MR. Squamous Cell Carcinoma Antigen (SCCA)-IgM levels kinetics during direct-acting antivirals (DAAs) in HCV infected patients with cirrhosis: a possible role to identify the individual risk of HCC development. Liver Gymnasium 4. Padova, Italy. 2017.
79. Biasiolo A, Martini A, Gallotta A, Fassina G, Pontisso P. Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications. Biom Liver Dis. 1-22. 2016. doi: 10.1007/978-94-007-7742-2_15-1
78. Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis. 48(2):197-202. 2016. doi: 10.1016/j.dld.2015.10.022
77. Cardoso H, Silva M, Barroso I, Guimarães T, Gonçalves R, Pereira P, Rodrigues S, Carneiro F, Macedo G. Avaliação da acuidade dos níveis séricos de SerpinB3 no diagnóstico de carcinoma hepatocelular. Congresso Português de Hepatologia. Porto, Portugal. 2016.
76. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Pontisso P, Romero-Gomez M. SCCA-IgM helps to identify patients at risk of long-term hepatocellular carcinoma. Hepatology. 64(S1):656A. 2016. doi: 10.1002/hep.28799
75. Silva M, Cardoso H, Barroso I, Guimaraes T, Goncalves R, Pereira P, Rodrigues S, Carneiro F, Macedo G. Accuracy of Squamous Cell Carcinoma Antigen-Immunoglobulin M complexes in the diagnosis of hepatocellular carcinoma. ILCA Annual Conference. Vancouver, Canada. 2016.
74. Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis. 5(4):59-66. 2015. doi: 10.5495/wjcid.v5.i4.59
73. Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical Validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Anal Methods. 7:629-637. 2015. doi: 10.1039/C4AY02495H
72. Gallotta A, Mràzovà V, Bednàrovà A, Kruzlicovà D, Frecer V, Miertus S, Fattovich G, Biasiolo A, Martini A, Ieluzzi D, Guido M, Pontisso P, Fassina G. A novel algorithm based on serum SCCA-IgM determination combined with common clinical data improves prediction of histological NASH. Dig Liver Dis. 47S:e226. 2015. doi: 10.1016/j.dld.2015.07.025
71. Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Farinati F. Squamous cellular carcinoma antigen serum determination as a biomarker of Barrett's esophagus and esophageal cancer: a phase III study. UEG Journal. 3:118. 2015. doi: 10.1177/2050640615601611
70. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat. 22(10):800-808. 2015. doi: 10.1111/jvh.12394
69. Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen immunoglobulins M to monitor chronic hepatitis C. World J Hepatol. 7(29):2913-2919. 2015. doi: 10.4254/wjh.v7.i29.2913
68. Montagnana M, Danese E, Lippi G. Squamous cell carcinoma antigen in hepatocellular carcinoma: ready for the prime time?. Clin Chim Acta. 445:161-166. 2015. doi: 10.1016/j.cca.2015.03.031
67. Morisco F, Guarino M, Di Costanzo GG, Gallotta A, Fassina G, Tortora R, Tuccillo C, Granata R, Loperto I, Auriemma F, Caporaso N. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. J Hepatol. 62:S450. 2015. doi: 10.1016/S0168-8278(15)30582-1
66. Pieri G, Marenco S, Lantieri F, Baldissarro I, Bruzzone L, Fazio V, Labanca S, Sammito G, Savarino V, Picciotto A. Serum SCCA-IgM can predict the development of HCC in patients with HCV-cirrhosis. Dig Liver Dis. 47:e59. 2015. doi: 10.1016/j.dld.2015.01.129
65. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 21(37):10573-10583. 2015. doi: 10.3748/wjg.v21.i37.10573
64. Zhang J, Shao C, Zhou Q, Zhu Y, Zhu J, Tu C. Diagnostic accuracy of serum squamous cell carcinoma antigen and serum squamous cell carcinoma antigen-immunoglobulin M for hepatocellular carcinoma: A meta-analysis. Mol Clin Oncol. 3:1165-1171. 2015. doi: 10.3892/mco.2015.600
63. Biasiolo A, Trotta E, Fasolato S, Tono N, Ruvoletto M, Martini A, Terrin L, Fassina G, Angeli P, Gatta A, Pontisso P. P569 SCCA-IgM is predictive of hepatocellular carcinoma development in patients with hcv cirrhosis. A prospective study. J Hepatol. 60:S259. 2014. doi: 10.1016/S0168-8278(14)60731-5
62. Fadini GP, Albiero M, Millioni R, Poncina N, Rigato M, Scotton R, Boscari F, Brocco E, Arrigoni G, Villano G, Turato C, Biasiolo A, Pontisso P, Avogaro A. The molecular signature of impaired diabetic wound healing identifies serpinB3 as a healing biomarker. Diabetologia. 57:1947-56. 2014. doi: 10.1007/s00125-014-3300-2
61. Gallotta A, Fassina G. Optical Biochips for Biomarkers-IgM Complexes Codetermination in Hepatocellular Carcinoma. . In Sensors (pp. 85-88). Springer New York. 2014.
60. Guarino M, Di Costanzo G G, Gallotta A, Fassina G, Tortora R, Tuccillo C, Auriemma F, Caporaso N, Morisco F. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. Dig Liver Dis. 46:e137. 2014. doi: 10.1016/j.dld.2014.08.020
59. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. Genotype 3 and circulating SCCA-IgM are independently associated with histological features of NASH in HCV infected patients. Dig Liver Dis. 46:e26. 2014. doi: 10.1016/j.dld.2014.01.061
58. Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. P837 Genotype 3 and circulating SCCA-IgM are independently associated with histological features of nash in hcv infected patients. J Hepatol. 60:S350-S351. 2014. doi: 10.1016/S0168-8278(14)60998-3
57. Mossad NA, Mahmoud EH, Osman EA, Mahmoud SH, Shousha HI. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IgM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumour Biol. 35:11559-64. 2014. doi: 10.1007/s13277-014-2467-y
56. Pontisso P. Role of SERPINB3 in hepatocellular carcinoma. Ann Hepatol. 13:722-727. 2014.
55. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Diagnostic and Prognostic Role of SCCA-IgM Serum Levels in Hepatocellular Carcinoma (Hcc). J Gastroenterol Hepatol. 29:1637-44. 2014. doi: 10.1111/jgh.12576
54. Biasiolo A, Tono N, Zaninotto M, Merkel C, Fassina G, Plebani M, Gatta A, Pontisso P. Specificity of squamous cell carcinoma antigen (SCCA)-IgM detection in patients with HCV infection and rheumatoid factor seropositivity. J Med Virol. 85:1005-8. 2013. doi: 10.1002/jmv.23493
53. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Auriemma F, Ferraiuoli C, Tuccillo C, Beneduce L, Caporaso N . SCCA-IgM: a biomarker to monitor the outcome of therapy with sorafenib in advanced HCC. Dig Liver Dis. 45:S217-18. 2013. doi: 10.1016/S1590-8658(13)60622-2
52. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Clery E, Auriemma F, Tuccillo C, Beneduce L, Caporaso N. Circulating SCCA-IgM complex is able to monitor the success of loco-regional therapy in HCC patients. Dig Liver Dis. 45:S218. 2013. doi: 10.1016/S1590-8658(13)60623-4
51. Morisco F, Di Costanzo GG, Guarino M, Tortora R, Loperto I, Tuccillo C, Ferraiuoli C, Beneduce L, Auriemma F, Caporaso N. Su1001 Circulating Scca-IgM Complex Is an Useful Biomarker to Monitor HCC Therapy. Gastroenterology. 144:S-991. 2013. doi: 10.1016/S0016-5085(13)63676-8
50. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 39:410-33. 2012. doi: 10.1053/j.seminoncol.2012.05.001
49. Biasiolo A, Tono N, Ruvoletto M, Quarta S, Turato C, Villano G, Beneduce L, Fassina G, Merkel C, Gatta A, Pontisso P. IgM-linked SerpinB3 and SerpinB4 in sera of patients with chronic liver disease. PLoS ONE. 7:e40658. 2012. doi: 10.1371/journal.pone.0040658
48. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Erroi V, Fazio V, Picciotto A, Biasiolo A, Degos F, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis. OJGas. 2:56-61. 2012. doi: 10.4236/ojgas.2012.22012
47. Fransvea E, Trerotoli P, Sacco R, Bernabucci V, Milella M, Napoli N, Mazzocca A, Renna E, Quaranta M, Angarano G, Villa E, Antonaci S, Giannelli G. SCCA-IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study. J Viral Hepat. 19:704-710. 2012. doi: 10.1111/j.1365-2893.2012.01604.x.
46. Gallotta A, Orzes E, Fassina G. Biomarkers Quantification with Antibody Arrays in Cancer Early Detection. Clin Lab Med. 32:33-45. 2012. doi: 10.1016/j.cll.2011.11.001
45. Morisco F, Guarino M, Tortora R, Donnarumma L, Loperto I, Camera S, Mariniello A, Tuccillo C, Beneduce L, Di Costanzo GG, Caporaso N . Serum Levels of SCCA-IgM are related to the efficacy of HCC treatments. Dig Liver Dis. 44:S135. 2012. doi: 10.1016/S1590-8658(12)60373-9
44. Pozzan C, Cardin R, Pichiocchi M, Cazzagon N, Sergio A, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). Dig Liver Dis. 44:S141-S142. 2012. doi: 10.1016/S1590-8658(12)60393-4
43. Zorzetto V, Maddalo G, Rugge M, Parente P, Zaninotto G, Ruol A, Biasiolo A, Zanatta L, Farinati F. SCCA-IgM determination in Barrett's esophagus and esophageal cancer might regulate endoscopic follow-up schedule. Dig Liver Dis. 44:S151. 2012. doi: 10.1016/S1590-8658(12)60420-4
42. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I. Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 102:363-71. 2011.
41. Biasiolo A, Tono N, Briarava M, Beneduce L, Fassina G, Farinati F, Giacomin A, Matteucci C, Sorrentino R, Nitti D, Gatta A , Pontisso P. Improved diagnostic accuracy for HCC using a combination of IgM-linked biomarkers. Dig Liver Dis. 43:S91. 2011. doi: 10.1016/S1590-8658(11)60081-9
40. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Fazio V, Picciotto A, Biasiolo A, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Dig Liver Dis. 43:S95. 2011. doi: 10.1016/S1590-8658(11)60094-7
39. Plebani M, Wu AH. Circulating macrocomplexes: old wine in new bottles?. Clin Chem Lab Med. 49:759-60. 2011. doi: 10.1515/cclm.2011.150
38. Pozzan C, Cardin R, Cazzagon N, Picciocchi M, vanin V, Giacomin A, Sergio P, Pontisso P, Farinati F. Diagnostic and prognostic role of SCCA-IgM in hepatocellular carcinoma (HCC). J Hepatol. 54: S101. 2011. doi: 10.1016/S0168-8278(11)60246-8
37. Zorzetto V, Rugge M, Parente P, Zaninotto G, Castoro M, Ruol A, Maddalo G, Zanatta L, Farinti F. SCCA-IgM and CEA-IgM in Barrett's esophagus and esophageal cancers. Dig Liver Dis. 43:S156. 2011.
36. Giannini EG, Basso M, Bazzica M, Contini P, Marenco S, Savarino V, Picciotto A. Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. J Viral Hepat. 17:563-568. 2010. doi: 10.1111/j.1365-2893.2009.01217.x
35. Savitskaya Y, Rico G, Linares L, Gonzalez R, Tellez R, Estrada E, Marin N, Martinez E, Alfaro A, Ibarra C. Circulating Natural IgM Antibodies Against Angiogenin in the Peripheral Blood Sera of Patients with Osteosarcoma as Candidate Biomarkers and Reporters of Tumorigenesis. Biomark Cancer. 2:65-78. 2010. doi: 10.4137/BIC.S6040
34. Stefaniuk P, Janusz Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 16:418-24. 2010.
33. Stefaniuk P, Krygier R, Dusza M, Jablonowska M, Mikula T, Dabrowska M, Cianciara J, Wiercinska-Drapalo A. Do we have more predictive HCC biomarkers? Usefulness of new generation of HCC biomarkers in immune complexes with immunoglobulins of the IgM class. Exp Clin Hep. 6:AB18-18. 2010.
32. Teofanescu I, Gologan E, Stefanescu G, Balan G. Surveillance of cirrhosis for hepatocellular carcinoma clinical validation of new serological biomarkers for improved hepatocellular carcinoma diagnosis. Rev Med Chir Soc Med Nat Iasi. 114:39-46. 2010.
31. Yim S, Chung Y. An Overview of Biomarkers and Molecular Signatures in HCC. Cancers (Basel). 2:809-23. 2010. doi: 10.3390/camcers2020809
30. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis. Clin Chem Lab Med. 48:217-23. 2010. doi: 10.1515/CCLM.2010.044
29. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. SCCA1-IgM and SCCA2-IgM compared with total SCCA-IgM for diagnosis of hepatocellular carcinoma. Int J Biol Markers. 24:205. 2009.
28. Carrara S, Bhalla V, Stagni C, Benini C, Ferretti A, Valle F, Gallotta A, Riccio B, Samorì B. Label-free cancer markers detection by capacitance biochip. Sens Actuators B Chem. 136:163-172. 2009. doi: 10.1016/j.snb.2008.09.050
27. Gallotta A, Pengo P, Beneduce L, Fassina G. Combinatorial approaches in cancer early detection. Drug Design and Discovery for Developing Countries (Eds. Megnassan E, Owono Owono L, Miertus S) ICS-UNIDO. 206-18. 2009.
26. Gallotta A, Zuin J, Veggiani G, Pengo P, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combining SCCA-IgM and AFP-IgM levels increases accuracy of hepatocellular carcinoma detection. Dig Liver Dis. 41:A15. 2009. doi: 10.1016/j.dld.2009.02.038
25. Gallotta A, Zuin J, Veggiani G, Pengo P, Leon A, Gion M, Biasiolo A, Tono N, Gatta A, Pontisso P, Fassina G, Beneduce L. Combination of biomarkers-IgM by logistic regression improves diagnostic accuracy in hepatocellular carcinoma. Int J Biol Markers. 24:208. 2009.
24. Kumar M, Sarin SK. Biomarkers of diseases in medicine. Current Trends in Science. 403-417. 2009.
23. Turato C, Ruvoletto MG, Biasiolo A, Quarta S, Tono N, Bernardinello E, Beneduce L, Fassina G, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P. Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis. 41:212-6. 2009. doi: 10.1016/j.dld.2008.06.001
22. Vidalino L, Doria A, Quarta S, Zen M, Gatta A, Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun Rev. 9:108-12. 2009. doi: 10.1016/j.autrev.2009.03.011
21. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Franzosi L, Pontisso P, Fassina G, Beneduce L. SCCA-IgM usefulness to monitor patients with cirrhosis is not affected by interfering IgM's. Dig Liver Dis. 41:A11. 2009. doi: 10.1016/j.dld.2009.02.031
20. Zuin J, Veggiani G, Pengo P, Gallotta A, Biasiolo A, Tono N, Gatta A, Pontisso P, Toth R, Cerin D, Frecer V, Meo S, Gion M, Fassina G, Beneduce L. Evaluation of the analytical specificity of SCCA-IgM assay for monitoring patients with cirrhosis. Int J Biol Markers. 24(3):209. 2009.
19. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasolo A, Tono N, Pontisso P, Fassina G. Hepatocellular carcinoma induces specific IgM-biomarkers immune complexes. Dig Liver Dis. 40:A32. 2008. doi: 10.1016/j.dld.2007.12.083
18. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat. 15:246-9. 2008. doi: 10.1111/j.1365-2893.2007.00935.x
17. Biasiolo A, Tono N, Quarta S, Beneduce L, Gatta A, Fassina G, Pontisso P. Squamous cell carcinoma antigen (SCCA)-IgM complex: SCCA1-IgM and SCCA-IgM compared to total SCCA-IgM for diagnosis of hepatocellular carcinoma. Gut. 57:A147. 2008.
16. Cagol M, Ruol A, Biasiolo A, Zanchettin G, Tono N, Castoro C, Alfieri R, Pontisso P, Ancona E. Serum squamous cell carcinoma antigen-IgM (SCCA-IgM) immunocomplex: a new biomarker. Gut. 57:A113. 2008.
15. Plebani M. Epatocarcinoma - Biomarcatori Sierologici. . In La scienza nascosta che salva le vite. Vol. 2: I biomarcatori (p. 103). Libreria Internazionale Cortina Padova. 2008.
14. Giannelli G, Antonaci S. Hepatocellular carcinoma: tumoral or peritumoral disease?. Recenti Prog Med. 98(1):23-8. 2007. doi: 10.1701/197.2057
13. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 383:147-52. 2007. doi: 10.1016/j.cca.2007.05.014
12. Giannelli G, Iannone F, Fransvea E, Chialà A, Lapadula G, Antonaci S. Squamous cellular carcinoma immunocomplex is increased in scleroderma patients with lung fibrosis. Clin Exp Rheumatol. 25:794-5. 2007.
11. Turato C, Ruvoletto M, Biasiolo A, Quarta S, Tono N, Cavalletto L, Chemello L, Merkel C, Gatta A, Pontisso P. HFE, TGF-BETA1 and squamous cell carcinoma antigen-1 polymorphisms and liver disease stage in chronic HCV infection. Dig Liver Dis. 39:A27. 2007. doi: dx.doi.org/10.1016/j.dld.2006.12.090
10. Beneduce L, Gallotta A, Marino M, Fassina G. Improvement of sensitivity for liver cancer detection by simultaneous evaluation of SCCA-IgM, AFP-IgM complexes and free AFP. J Hepatol. 44:S97. 2006. doi: 10.1016/S0168-8278(06)80242-4
9. Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis. 38:854-9. 2006. doi: 10.1016/j.dld.2006.05.007
8. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Boscato N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer. 119:735-40. 2006. doi: 10.1002/ijc.21908
7. Quarta S, Caberlotto C, Beneduce L, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Monitoring SCCA-IgM complex predicts HCC development in cirrhotic patients. J Hepatol. 44:S107. 2006.
6. Beneduce L, Castaldi F, Marino M, Pontisso P, Fassina G. Comparison of free and IgM-complexed squamous cell carcinoma antigen in hepatocellular carcinoma. J Hepatol. 42:89. 2005.
5. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 103:2558-65. 2005. doi: 10.1002/cncr.21106
4. Quarta S, Caberlotto C, Beneduce L, Castaldi F, Marino M, Fassina G, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Serum SCCA-IgM complexes increase over time and HCC development in cirrhotic patients. Dig Liver Dis. 37:A38-A39. 2005.
3. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Circulating squamous cell carcinoma antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma. Dig Liver Dis. 36:A2-A3. 2004.
2. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Pontisso P, Fassina G. Serological detection of squamous cell carcinoma antigen-IgM complexes in hepatocellular carcinoma. J Hepatol. 40:77. 2004. doi: 10.1016/S0168-8278(04)90244-9
1. Pontisso P, Fassina G, Quarta S, Ruvoletto M, Tono N, Castaldi F, Nigro A, Marino M, Beneduce L, Gatta A. Nanotecnologie nella diagnostica dell'epatocarcinoma. Atti del 14° Conv. Int. Attualità e Prospettive in Epatologia. 144-8. 2004.